Picoplatin
From Wikipedia, the free encyclopedia
| Picoplatin | ||
|---|---|---|
 | ||
| IUPAC name azane; 2-methylpyridine; platinum(2+); dichloride | ||
| Identifiers | ||
| CAS number | 181630-15-9  | |
| PubChem | 177358 | |
| Jmol-3D images | {{#if:CC1=CC=CC=N1.N.[Cl-].[Cl-].[Pt+2]|Image 1 | |
| ||
| Properties | ||
| Molecular formula | C6H10Cl2N2Pt | |
| Molar mass | 376.15 g mol−1 | |
(verify) (what is: / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C (77 °F), 100 kPa) | ||
| Infobox references | ||
Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]
References
- ↑ The status of platinum anticancer drugs in the clinic and in clinical trials Dalton Transactions
- ↑ Picoplatin Clinical Results, Poniard Pharmaceuticals
- ↑ Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
- ↑ http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009
| ||||||||||||||||||||||
This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.